Related references
Note: Only part of the references are listed.The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
Gareth J. Morgan et al.
BLOOD (2012)
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results
Gareth J. Morgan et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation
Gareth J. Morgan et al.
BLOOD (2011)
Guidelines for the diagnosis and management of multiple myeloma 2011
Jennifer M. Bird et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
Gareth J. Morgan et al.
LANCET ONCOLOGY (2011)
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J. Morgan et al.
LANCET (2010)
Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010
Hermann Brenner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
Robert A. Kyle et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients - May 2006
Richard Weitzman et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement
Brian G. M. Durie
MAYO CLINIC PROCEEDINGS (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma
Martha Q. Lacy et al.
MAYO CLINIC PROCEEDINGS (2006)
Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma
EV McCloskey et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
